A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects With Advanced Stage Solid Tumors
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAS3847
U.S. Govt. ID: NCT03926013
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find a safe dose of JNJ-63898081 that can be used for further studies in subjects with advanced cancers such as metastatic castration resistant prostate cancer (mCRPC) or metastatic kidney cancer, also referred to as renal cell carcinoma. This is a Phase 1 study and the first time JNJ-63898081 is being given to humans.
This study is closed
Emerson Lim, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with metastatic renal cell carcinoma or metastatic castration resistant prostate cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator